Cartesian Therapeutics
RNAC
87 hedge funds and large institutions have $57.2M invested in Cartesian Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 13 closing their positions.
2,900% more call options, than puts
Call options by funds: $90K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.05% less ownership
Funds ownership: 1.23% → 1.17% (-0.05%)
5% less funds holding
Funds holding: 92 → 87 (-5)
10% less capital invested
Capital invested by funds: $63.2M → $57.2M (-$6.04M)
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$4.46M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.34M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$323K |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$223K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.68M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.43M |
| 3 |
Millennium Management
New York
|
-$1.38M |
| 4 |
JP Morgan Chase
New York
|
-$608K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$424K |
RNAC Hedge Fund Activity: Q3 2023 in Review
87 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2023, worth a combined $57.2M — down 9.6% from $63.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RNAC and 8 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 22 added.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $4.46M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.68M sold.
- 87 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2023, down from 92 in Q2 2023.
- Funds reported $57.2M of Cartesian Therapeutics stock for Q3 2023, down 9.6% quarter-over-quarter.
- 8 funds opened new Cartesian Therapeutics positions in Q3 2023 and 13 closed out, a net change of -5 holders.
- The largest Cartesian Therapeutics buyer in Q3 2023 was Madison Avenue Partners, an estimated $4.46M added.
- The largest Cartesian Therapeutics seller in Q3 2023 was Boxer Capital, an estimated $3.68M sold.
Based on aggregated 13F filings for Q3 2023.